0001209191-18-008219.txt : 20180207
0001209191-18-008219.hdr.sgml : 20180207
20180207180856
ACCESSION NUMBER: 0001209191-18-008219
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180205
FILED AS OF DATE: 20180207
DATE AS OF CHANGE: 20180207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: OBrien Christopher Flint
CENTRAL INDEX KEY: 0001343124
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 18582220
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-05
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001343124
OBrien Christopher Flint
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Former Chief Medical Officer
Common Stock
2018-02-05
4
S
0
1500
83.0147
D
52223
D
Common Stock
2018-02-05
4
S
0
1113
83.3957
D
54310
D
Common Stock
2018-02-06
4
F
0
1014
82.48
D
55946
D
Stock Option
81.49
2018-02-05
4
A
0
9250
0.00
A
2028-02-05
Common Stock
9250
9250
D
Sale of 1,500 shares of common stock issued upon vesting of 3,000 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,500) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in
a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the
Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 1,113 shares of common stock issued upon vesting of restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (2,087) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in
a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the
Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Payment of tax liability by withholding 1,014 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,636) maintained by the Reporting Person.
Represents option of which 1/24th of the shares underlying the option becomes vested and exercisable on March 5, 2018 and an additional 1/24th of the shares underlying the option becomes vested and exercisable each month thereafter.
/s/ Darin Lippoldt, Attorney-in-Fact
2018-02-07